{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:28:10Z","timestamp":1791584890961,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-09528-8","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:54:19Z","timestamp":1768478059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["IL-15 overexpression promotes memory program and anti-tumor activity of CD64 CAR T cells in a preclinical AML model"],"prefix":"10.1038","volume":"9","author":[{"given":"Lingling","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3035-4235","authenticated-orcid":false,"given":"Haidong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3706-3139","authenticated-orcid":false,"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2855-5871","authenticated-orcid":false,"given":"Xiaoming","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"9528_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"9528_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner, H. et al. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453\u2013474 (2010).","journal-title":"Blood"},{"key":"9528_CR3","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","volume":"10","author":"S Venugopal","year":"2024","unstructured":"Venugopal, S. & Sekeres, M. A. Contemporary management of acute myeloid leukemia: a review. JAMA Oncol. 10, 1417\u20131425 (2024).","journal-title":"JAMA Oncol."},{"key":"9528_CR4","unstructured":"National Cancer Institute Cancer Stat Facts: Leukemia\u2014Acute Myeloid Leukemia (AML) [(accessed on 4 April 2022)]. https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"9528_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood.2019001982","volume":"136","author":"S DeWolf","year":"2020","unstructured":"DeWolf, S. & Tallman, M. S. How I treat relapsed or refractory AML. Blood 136, 1023\u20131032 (2020).","journal-title":"Blood"},{"key":"9528_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen, J. J. & Blaise, D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127, 62\u201370 (2016).","journal-title":"Blood"},{"key":"9528_CR7","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson, G. et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113, 4179\u20134187 (2009).","journal-title":"Blood"},{"key":"9528_CR8","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. https:\/\/www.nccn.org\/professionals\/physiciangls\/pdf\/aml.pdf."},{"key":"9528_CR9","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.12669\/pjms.38.5.5249","volume":"38","author":"I Shireen","year":"2022","unstructured":"Shireen, I., Komal, S., Ansari, A. M. & Meraj, L. Frequency of complete remission after standard 3+7 induction therapy in patients with acute myeloid leukemia. Pak. J. Med. Sci. 38, 1138\u20131142 (2022).","journal-title":"Pak. J. Med. Sci."},{"key":"9528_CR10","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro, F. P. et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia 35, 3282\u20133286 (2021).","journal-title":"Leukemia"},{"key":"9528_CR11","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3389\/fonc.2019.01358","volume":"9","author":"S Yao","year":"2019","unstructured":"Yao, S. et al. Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML. Front. Oncol. 9, 1358 (2019).","journal-title":"Front. Oncol."},{"key":"9528_CR12","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","volume":"27","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed\/refractory acute myeloid leukemia. Clin. Cancer Res. 27, 3549\u20133555 (2021).","journal-title":"Clin. Cancer Res."},{"key":"9528_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","volume":"28","author":"GS Laszlo","year":"2014","unstructured":"Laszlo, G. S., Estey, E. H. & Walter, R. B. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 28, 143\u2013153 (2014).","journal-title":"Blood Rev."},{"key":"9528_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7866","volume":"6","author":"M Kiyoshi","year":"2015","unstructured":"Kiyoshi, M. et al. Structural basis for binding of human IgG1 to its high-affinity human receptor Fc\u03b3RI. Nat. Commun. 6, 6866 (2015).","journal-title":"Nat. Commun."},{"key":"9528_CR15","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood.V73.7.1951.1951","volume":"73","author":"ED Ball","year":"1989","unstructured":"Ball, E. D. et al. Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells. Blood 73, 1951\u20131956 (1989).","journal-title":"Blood"},{"key":"9528_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12350","volume":"268","author":"P Bruhns","year":"2015","unstructured":"Bruhns, P. & J\u00f6nsson, F. Mouse and human FcR effector functions. Immunol. Rev. 268, 25\u201351 (2015).","journal-title":"Immunol. Rev."},{"key":"9528_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/CJI.0000000000000406","volume":"45","author":"X Sun","year":"2022","unstructured":"Sun, X. et al. Preclinical evaluation of CD64 as a potential target for CAR-T-cell therapy for acute myeloid leukemia. J. Immunother. 45, 67\u201377 (2022).","journal-title":"J. Immunother."},{"key":"9528_CR18","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","volume":"30","author":"AS Bhagwat","year":"2024","unstructured":"Bhagwat, A. S. et al. Cytokine-mediated CAR T therapy resistance in AML. Nat. Med. 30, 3697\u20133708 (2024).","journal-title":"Nat. Med."},{"key":"9528_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fonc.2020.00262","volume":"10","author":"R Epperly","year":"2020","unstructured":"Epperly, R., Gottschalk, S. & Velasquez, M. P. A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy. Front. Oncol. 10, 262 (2020).","journal-title":"Front. Oncol."},{"key":"9528_CR20","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1073\/pnas.0307298101","volume":"101","author":"CA Klebanoff","year":"2004","unstructured":"Klebanoff, C. A. et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA 101, 1969\u20131974 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9528_CR21","doi-asserted-by":"publisher","first-page":"e008572","DOI":"10.1136\/jitc-2023-008572","volume":"12","author":"I S\u00e1nchez-Moreno","year":"2024","unstructured":"S\u00e1nchez-Moreno, I. et al. Tethered IL15-IL15R\u03b1 augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model. J. Immunother. Cancer 12, e008572 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"9528_CR22","doi-asserted-by":"publisher","first-page":"e001229","DOI":"10.1136\/jitc-2020-001229","volume":"8","author":"Ataca","year":"2020","unstructured":"Ataca et al. Modulating TNFalpha activity allows transgenic Il15-expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J. Immunother. Cancer 8, e001229 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"9528_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","volume":"8","author":"SA Batra","year":"2020","unstructured":"Batra, S. A. et al. Glypican-3-specific CAR T cells coexpressing Il15 and Il21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol. Res. 8, 309\u2013320 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"9528_CR24","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.3390\/cancers15102713","volume":"15","author":"E Atilla","year":"2023","unstructured":"Atilla, E. & Benabdellah, K. The black hole: CAR T cell therapy in AML. Cancers 15, 2713 (2023).","journal-title":"Cancers"},{"key":"9528_CR25","doi-asserted-by":"publisher","first-page":"103423","DOI":"10.1016\/j.xpro.2024.103423","volume":"5","author":"T Nguyen","year":"2024","unstructured":"Nguyen, T. et al. Protocol to measure human IL-6 secretion from CAR T cell-primed macrophage and monocyte lineage cells in vitro and in vivo using humanized mice. STAR Protoc. 5, 103423 (2024).","journal-title":"STAR Protoc."},{"key":"9528_CR26","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh, D. et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol. Res. 7, 759\u2013772 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"9528_CR27","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1182\/blood-2010-10-310599","volume":"117","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 117, 1888\u20131898 (2011).","journal-title":"Blood"},{"key":"9528_CR28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1172\/JCI32103","volume":"118","author":"C Berger","year":"2008","unstructured":"Berger, C. et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294\u2013305 (2008).","journal-title":"J. Clin. Invest."},{"key":"9528_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller, N., Anderson, A. C. & Kuchroo, V. K. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity 57, 206\u2013222 (2024).","journal-title":"Immunity"},{"key":"9528_CR30","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","volume":"355","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst, A. O. et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355, 1423\u20131427 (2017).","journal-title":"Science"},{"key":"9528_CR31","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1084\/jem.20071913","volume":"205","author":"E Mortier","year":"2008","unstructured":"Mortier, E., Woo, T., Advincula, R., Gozalo, S. & Ma, A. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J. Exp. Med. 205, 1213\u20131225 (2008).","journal-title":"J. Exp. Med."},{"key":"9528_CR32","doi-asserted-by":"publisher","first-page":"1141208","DOI":"10.3389\/fimmu.2023.1141208","volume":"14","author":"P Sindaco","year":"2023","unstructured":"Sindaco, P. et al. The role of interleukin-15 in the development and treatment of hematological malignancies. Front. Immunol. 14, 1141208 (2023).","journal-title":"Front. Immunol."},{"key":"9528_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004104","volume":"10","author":"JA Hangasky","year":"2022","unstructured":"Hangasky, J. A. et al. A very long-acting IL-15: implications for the immunotherapy of cancer. J. Immunother. Cancer 10, e004104 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"9528_CR34","first-page":"85","volume":"7","author":"J Wu","year":"2013","unstructured":"Wu, J. IL-15 agonists: the cancer cure cytokine. J. Mol. Genet. Med. 7, 85 (2013).","journal-title":"J. Mol. Genet. Med."},{"key":"9528_CR35","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","volume":"3","author":"S Cooley","year":"2019","unstructured":"Cooley, S. et al. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv. 3, 1970\u20131980 (2019).","journal-title":"Blood Adv."},{"key":"9528_CR36","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1084\/jem.20020066","volume":"195","author":"JT Tan","year":"2002","unstructured":"Tan, J. T. et al. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med. 195, 1523\u20131532 (2002).","journal-title":"J. Exp. Med."},{"key":"9528_CR37","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1182\/blood-2011-04-349746","volume":"118","author":"L Yang","year":"2011","unstructured":"Yang, L. et al. Homeostatic cytokines orchestrate the segregation of CD4 and CD8 memory T-cell reservoirs in mice. Blood 118, 3039\u20133050 (2011).","journal-title":"Blood"},{"key":"9528_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","volume":"36","author":"GJ van der Windt","year":"2012","unstructured":"van der Windt, G. J. et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36, 68\u201378 (2012).","journal-title":"Immunity"},{"key":"9528_CR39","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1242\/dev.057323","volume":"138","author":"P Squarzoni","year":"2011","unstructured":"Squarzoni, P., Parveen, F., Zanetti, L., Ristoratore, F. & Spagnuolo, A. FGF\/MAPK\/Ets signaling renders pigment cell precursors competent to respond to Wnt signal by directly controlling Ci-Tcf transcription. Development 138, 1421\u20131432 (2011).","journal-title":"Development"},{"key":"9528_CR40","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","volume":"127","author":"H Clevers","year":"2006","unstructured":"Clevers, H. Wnt\/beta-catenin signaling in development and disease. Cell 127, 469\u2013480 (2006).","journal-title":"Cell"},{"key":"9528_CR41","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nm.1982","volume":"15","author":"L Gattinoni","year":"2009","unstructured":"Gattinoni, L. et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 15, 808\u2013813 (2009).","journal-title":"Nat. Med."},{"key":"9528_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04982-6","volume":"22","author":"J Ye","year":"2024","unstructured":"Ye, J. et al. Combined therapy of CAR-IL-15\/IL-15R\u03b1-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer. J. Transl. Med. 22, 171 (2024).","journal-title":"J. Transl. Med."},{"key":"9528_CR43","doi-asserted-by":"publisher","first-page":"101161","DOI":"10.1016\/j.xcrm.2023.101161","volume":"4","author":"M Boulch","year":"2023","unstructured":"Boulch, M. et al. A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy. Cell Rep. Med. 4, 101161 (2023).","journal-title":"Cell Rep. Med."},{"key":"9528_CR44","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41590-023-01720-w","volume":"25","author":"X Zhao","year":"2024","unstructured":"Zhao, X. et al. The transcriptional cofactor Tle3 reciprocally controls effector and central memory CD8+ T cell fates. Nat. Immunol. 25, 294\u2013306 (2024).","journal-title":"Nat. Immunol."},{"key":"9528_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","journal-title":"Nat. Commun."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09528-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09528-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09528-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:06:47Z","timestamp":1771434407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09528-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9528"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-09528-8","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"251"}}